IRESSA 250 (Iressa 250 mg)

Generic Name: gefitinib

Pill with imprint IRESSA 250 is Brown, Round and has been identified as Iressa 250 mg. It is supplied by AstraZeneca Pharmaceuticals.

Iressa is used in the treatment of non-small cell lung cancer and belongs to the drug class EGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Iressa 250 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for IRESSA 250

Iressa

Generic Name:

gefitinib

Imprint:

IRESSA 250

Strength:

250 mg

Color:

Brown

Size:

11.00 mm

Shape:

Round

Availability:

Prescription only

Drug Class:

EGFR inhibitors

Pregnancy Category:

D - Positive evidence of risk

CSA Schedule:

Not a controlled drug

Labeler / Supplier:

AstraZeneca Pharmaceuticals

National Drug Code (NDC):

00310-0482

Inactive Ingredients:

lactose monohydrate
microcrystalline cellulose
croscarmellose sodium
povidone
sodium lauryl sulfate
magnesium stearate
hypromelloses
polyethylene glycol 300
titanium dioxide
ferric oxide red
ferric oxide yellow
Note: Inactive ingredients may vary.

More Info Imprint SearchPrint

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer